Brown Melinda
Known title: DirectorCIK: 0001682988
Brown Melinda's purchase track record
How the stock did after each of Brown Melinda's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 6 since December 26, 2024
Stock higher 6 months later
80%
3 months: 40%
Median 6-month return
+13.3%
3 months: -3.9%
Beat the S&P 500
40%
median -3.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/25/2026 | DTIL | $7K | pending | pending | — |
| 12/15/2025 | DTIL | $7K | +31.3% | +29.4% | +10.8% |
| 9/22/2025 | DTIL | $7K | -10.7% | +34.2% | -1.7% |
| 6/25/2025 | DTIL | $7K | +21.0% | +1.2% | +13.8% |
| 3/26/2025 | DTIL | $9K | -6.4% | +13.3% | +16.2% |
| 12/26/2024 | DTIL | $14K | -3.9% | -12.4% | +1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DTIL | ▲ Buy | Open Market | 1,135 | $7K | 9/25/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 | View on chart |
| DTIL | ▲ Buy | Open Market | 1,381 | $7K | 12/15/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 1,400 | $7K | 9/22/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 1,682 | $7K | 6/25/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 1,839 | $9K | 3/26/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 3,016 | $14K | 12/26/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.